

RECEIVED

NOV 18 2003

TECH CENTER 1600/2900

BRYAN CAVE



November 7, 2003

Commissioner for Patents
Washington, DC 20231

Re: United States Patent Application
Serial No.: 09/871,441
Filed: May 31, 2001
For: METHOD FOR IMPROVING TREATMENT
SELECTIVITY AND EFFICACY USING
INTRAVASCULAR PHOTODYNAMIC THERAPY
Our Reference Number: C017858/0120103

Sir:


Enclosed please find the following documents to be filed in connection with the above-referenced patent application:

1. Transmittal letter (1 page, in duplicate);
2. Fee Transmittal for FY 2004 (1 page);
3. Petition for Extension of Time Under 37 CFR § 1.136(a) (6 pages);
4. Request for Continued Examination (RCE) Transmittal (1 page);
5. Check in the amount of \$860.00 for filing fees for extension and Request for Examination; and
6. Return postcard.

If our check is missing or is insufficient, please charge any additional fee or credit any overpayment to Deposit Account No. 02-4467.

Kindly date-stamp and return the enclosed self-addressed, stamped postcard. Should you have any questions regarding the enclosed materials, please do not hesitate to contact us.

Very truly yours,



Roxana Wizorek

RW:mfw
Enclosures

Roxana Wizorek
Direct: (314) 259-2699
rwizorek@bryancave.com

Bryan Cave LLP
One Metropolitan Square
211 North Broadway
Suite 3600
St. Louis, MO 63102-2750
Tel (314) 259-2000
Fax (314) 259-2020
www.bryancave.com

Chicago
Hong Kong
Irvine
Jefferson City
Kansas City
Kuwait
Los Angeles
New York
Phoenix
Riyadh
Shanghai
St. Louis
United Arab Emirates (Dubai)
Washington, DC

*And Bryan Cave,
A Multinational Partnership,
London*

RECEIVED

NOV 18 2003

TECH CENTER 1600/2900

BRYAN CAVE



November 7, 2003

Commissioner for Patents
Washington, DC 20231

Re: United States Patent Application
Serial No.: 09/871,441
Filed: May 31, 2001
For: METHOD FOR IMPROVING TREATMENT
SELECTIVITY AND EFFICACY USING
INTRAVASCULAR PHOTODYNAMIC THERAPY
Our Reference Number: C017858/0120103

Sir:

Enclosed please find the following documents to be filed in connection with the above-referenced patent application:

1. Transmittal letter (1 page, in duplicate);
2. Fee Transmittal for FY 2004 (1 page);
3. Petition for Extension of Time Under 37 CFR § 1.136(a) (6 pages);
4. Request for Continued Examination (RCE) Transmittal (1 page);
5. Check in the amount of \$860.00 for filing fees for extension and Request for Examination; and
6. Return postcard.

If our check is missing or is insufficient, please charge any additional fee or credit any overpayment to Deposit Account No. 02-4467.

Kindly date-stamp and return the enclosed self-addressed, stamped postcard. Should you have any questions regarding the enclosed materials, please do not hesitate to contact us.

Very truly yours,



Roxana Wizorek


RW:mfw
Enclosures

Roxana Wizorek
Direct: (314) 259-2699
rwizorek@bryancave.com

Bryan Cave LLP
One Metropolitan Square
211 North Broadway
Suite 3600
St. Louis, MO 63102-2750
Tel (314) 259-2000
Fax (314) 259-2020
www.bryancave.com

Chicago
Hong Kong
Irvine
Jefferson City
Kansas City
Kuwait
Los Angeles
New York
Phoenix
Riyadh
Shanghai
St. Louis
United Arab Emirates (Dubai)
Washington, DC

*And Bryan Cave,
A Multinational Partnership,
London*



RCE/1614 #

PTO/SB/30 (09-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2006. GPO:2005-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request
for
Continued Examination (RCE)
Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	09/871,441
Filing Date	May 31, 2001
First Named Inventor	Steven J. Rychnovsky
Art Unit	1614
Examiner Name	R. Henley, III
Attorney Docket Number	17859/120103

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Roxana Wizorek	Registration No. (Attorney/Agent)	46,110
Signature		Date	November 7, 2003

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Roxana Wizorek	Signature		Date	November 7, 2003
-------------------	----------------	-----------	---	------	------------------

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

11/17/2003 AWONDAF1 00000122 09871441

01 FC-2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CANCELLLED

NOV 13 2003
PATENT & TRADEMARK OFFICE

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 860.00)

Complete if Known

Application Number	09,871,441
Filing Date	May 31, 2001
First Named Inventor	Steven J. Rychnovsky
Examiner Name	R. Henley, III
Art Unit	1614
Attorney Docket No.	17858/120103

RECEIVED
TECH CENTER 1500
NOV 13 2003**METHOD OF PAYMENT (check all that apply)**

Check Credit card Money Order Other None

Deposit Account:

Deposit Account Number	02-4467
Deposit Account Name	Bryan Cave LLP

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) or any underpayment of fee(s)
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1001	2001	770	385	Utility filing fee	
1002	2002	340	170	Design filing fee	
1003	2003	530	265	Plant filing fee	
1004	2004	770	385	Reissue filing fee	
1005	2005	160	80	Provisional filing fee	
SUBTOTAL (1) (\$)					

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid

Large Entity	Small Entity	Fee Description
1202	2202	18 9 Claims in excess of 20
1201	2201	86 43 Independent claims in excess of 3
1203	2203	290 145 Multiple dependent claim, if not paid
1204	2204	86 43 ** Reissue independent claims over original patent
1205	2205	18 9 ** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)		

*or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051	2051	130	65	Surcharge - late filing fee or oath	
1052	2052	50	25	Surcharge - late provisional filing fee or cover sheet	
1053	1053	130	130	Non-English specification	
1812	1812	2,520	2,520	For filing a request for ex parte reexamination	
1804	1804	920*	920*	Requesting publication of SIR prior to Examiner action	
1805	1805	1,840*	1,840*	Requesting publication of SIR after Examiner action	
1251	2251	110	55	Extension for reply within first month	
1252	2252	420	210	Extension for reply within second month	\$475.00
1253	2253	950	475	Extension for reply within third month	
1254	2254	1,480	740	Extension for reply within fourth month	
1255	2255	2,010	1,005	Extension for reply within fifth month	
1401	2401	330	165	Notice of Appeal	
1402	2402	330	165	Filing a brief in support of an appeal	
1403	2403	290	145	Request for oral hearing	
1451	1451	1,510	1,510	Petition to institute a public use proceeding	
1452	2452	110	55	Petition to revive - unavoidable	
1453	2453	1,330	665	Petition to revive - unintentional	
1501	2501	1,330	665	Utility issue fee (or reissue)	
1502	2502	480	240	Design issue fee	
1503	2503	640	320	Plant issue fee	
1460	1460	130	130	Petitions to the Commissioner	
1807	1807	50	50	Processing fee under 37 CFR 1.17(q)	
1806	1806	180	180	Submission of Information Disclosure Stmt	
8021	8021	40	40	Recording each patent assignment per property (times number of properties)	
1809	2809	770	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	2810	770	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	2801	770	385	Request for Continued Examination (RCE)	\$385.00
1802	1802	900	900	Request for expedited examination of a design application	
Other fee (specify) _____					
*Reduced by Basic Filing Fee Paid					SUBTOTAL (3) (\$) 860.00

SUBMITTED BY


(Complete if applicable)

Name (Print/Type)	Roxana Wizorek	Registration No. (Attorney/Agent)	46,110	Telephone	314-259-2699
Signature	<i>Roxana Wizorek</i>			Date	November 7, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Docket No.: C17858/120103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 18 2003

TECH CENTER 1600/2900

In re Application of:

STEVEN J. RYCHNOVSKY

Serial No.: 09/871,441

Examiner: R. Henley, III

Filed: May 31, 2001

Art Unit: 1614

For: METHOD FOR IMPROVING
TREATMENT SELECTIVITY AND
EFFICACY USING INTRAVASCULAR
PHOTODYNAMIC THERAPY

Assistant Commissioner for Patents
Washington, D.C. 20231

Petition for Extension of Time Under 37 CFR § 1.136(a)

Applicant respectfully petitions for a three (3) month extension of time to respond to the outstanding Office Action issued on May 9, 2003, in the above-captioned patent application. A check for the extension fee of \$475.00 is enclosed. If our check is missing or otherwise insufficient, or if any additional fees are required, please charge (or credit any overpayment) to Deposit Account No. 02-4467.

Amendment

In the Claims

Please amend the following claims:

1. (Amended) A method of PDT treatment of cardiovascular indications associated with occlusions of a blood vessel comprising the steps of:
administering a photosensitizing drug other than psoralen compounds; and
delivering intravascular photoactivating light to the blood vessel at an activation wavelength within the range of about 390 to 610 nm such that the molar extinction coefficient of the photosensitizer drug at